Cookies on this site
This website uses cookies to give you the best experience online and to provide anonymised, aggregated site usage data. You can find out what cookies we use, what they do and how you can disable them in our Cookie Policy. By browsing this website and closing this message, you consent to the use of cookies in accordance with our Cookie Policy unless you have disabled them.

Close this message

Success

Thanks for registering for future updates.
Continue

Discover the ADKeySuspect Virtual Booth: VISIT NOW

Interested in a treatment option for adults with moderate-to-severe
atopic dermatitis (eczema)?

Learn about a biologic treatment option
graphic created by ADKeySuspect.com of a magnifying glass and fingerprint with patient image not an actual patient for illustrative purposes only
Not an actual patient.
For illustrative purposes only.

EXPLORE A KEY SUSPECT BEHIND SIGNS AND SYMPTOMS OF ATOPIC DERMATITIS

Look closer at how Th2 cytokines, including IL-13, drive skin inflammation1-4
DISCOVER MORE FROM THE EXPERTS ►
woman with atopic dermatitis image

UNCOVER THE BURDEN OF DISEASE

The chronic, persistent nature of atopic dermatitis (AD) means it’s always there, even when patients may appear asymptomatic. The cycle of chronic itch and inflammation can have a significant impact on patients.1,4

UNCOVER MORE
Skin layers image

EXPLORE THE Th2 CYTOKINES 
THAT DRIVE AD

Th2 cytokines are the key drivers of the inflammatory cascade associated with atopic dermatitis. How these manifest can differ across non-lesional, acute lesional, and chronic lesional skin.5

EXPLORE MORE
IL-13 image

DISCOVER THE ROLE OF IL-13 IN AD

IL-13 plays a key role in the inflammation underlying AD signs and symptoms. In AD skin, overexpression of IL-13 leads to a variety of pathophysiologic issues, including disruption of the skin barrier and amplified inflammation.6-12

DISCOVER MORE

References

  1. Suárez-Fariñas M, Tintle S, Shemer A, et al. Non-lesional atopic dermatitis (AD) skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol. 2011;127(4):954-964.e1-4.
  2. Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis. Arch Dermatol Res. 2004;295(11):459-464.
  3. Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of Th2/Th22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344-1354.
  4. Silverberg JI, Kantor R. The role of interleukins 4 and/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin. 2017;35(3):327-334.
  5. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1-20.
  6. Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 2008;126(3):332-337.
  7. Berdyshev E, Golvea E, Bronova I, et al. Lipid abnormalities in atopic skin are driven by type 2 cytokines. JCI Insight. 2018;3(4):e98006.
  8. Nomura I, Goleva E, Howell MD, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes.
    J Immunol. 2003;171(6):3262-3269.
  9. Purwar R, Werfel T, Wittmann M. IL-13-stimulated human keratinocytes preferentially attract CD4+CCR4+ T cells: possible role in atopic dermatitis. J Invest Dermatol. 2006;126(5):1043-1051.
  10. Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217-28.e13.
  11. Moriya C, Jinnin M, Yamane K, et al. Expression of matrix metalloproteinase-13 is controlled by IL-13 via PI3K/Akt3 and PKC-δ in normal human dermal fibroblasts.
    J Invest Dermatol. 2011;131(3):655-661.
  12. Mack MR, Kim BS. The itch-scratch cycle: a neuroimmune perspective. Trends Immunol. 2018;39(12):980-991.